Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
M.D. Anderson Cancer Center |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00048100 |
Condition | Intervention | Phase |
---|---|---|
Leukemia, Myelocytic, Acute |
Procedure: Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes for Therapy of Relapsed Leukemia After Allogeneic Stem Cell Therapy |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion:
Exclusion:
Study ID Numbers: | ID00-034 |
Study First Received: | October 24, 2002 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00048100 |
Health Authority: | United States: Food and Drug Administration |
Dendritic cells Lymphocytes AML |
Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute |
Neoplasms Neoplasms by Histologic Type |